Tigilanol tiglate (TT) is a protein kinase C (PKC)/C1 domain activator currently being developed as an intralesional agent for the treatment of various (sub)cutaneous malignancies. Previous work has shown that intratumoral (I.T.) injection of TT causes vascular disruption with concomitant tumor ablation in several preclinical models of cancer, in addition to various (sub)cutaneous tumors presenting in the veterinary clinic. TT has completed Phase I dose escalation trials, with some patients showing signs of abscopal effects. However, the exact molecular details underpinning its mechanism of action (MoA), together with its immunotherapeutic potential in oncology remain unclear.
| Authors | Cullen, JK; Yap, PY; Ferguson, B; Bruce, ZC; Koyama, M; Handoko, H; Hendrawan, K; Simmons, JL; Brooks, KM; Johns, J; Wilson, ES; de Souza, MMA; Broit, N; Stewart, P; Shelley, D; McMahon, T; Ogbourne, SM; Nguyen, TH; Lim, YC; Pagani, A; Appendino, G; Gordon, VA; Reddell, PW; Boyle, GM; Parsons, PG |
|---|---|
| Journal | Journal for immunotherapy of cancer |
| Pages | |
| Volume | 12 |
| Date | 24/05/2024 |
| Grant ID | 75N92020D00005 | NHLBI NIH HHS [HL] (United States); 75N93022D00005 | NIAID NIH HHS [AI] (United States); 75N99020D00005 | ORFDO NIH HHS [OF] (United States); 75N95020D00005 | NIDA NIH HHS [DA] (United States); 75N93023D00005 | NIAID NIH HHS [AI] (United States) |
| Funding Body | |
| URL | http://www.ncbi.nlm.nih.gov/pubmed/?term=10.1136/jitc-2022-006602 |